1st Qtr Report, page-6

AS per what Dr Cowens words on the 17th March at the conference call, all trials have provisions to be stopped , It may become unethical to deny those patients in the control arm the therapy should those the treatment arm are doing so well , there is a very good chance when we head for the 100 patients enrolled this will become obvious to the trial investigators , yet another alpha buying opportunity presents itself, good luck investors